achieve adequate flows (cardiac output) and LV decompression. The pump speed during the post implantation hospitalization (and at subsequent outpatient clinic visits) was adjusted under echocardiographic guidance to achieve a midline position of the interventricular and interatrial septum and minimum mitral valve regurgitation. Intermittent aortic valve opening was desirable but not always achieved.
A2. Myocardial tissue acquisition:
LV apex was collected at the time of LVAD implantation. A corresponding piece of tissue was collected at the time of transplantation. Myocardial tissue was divided into pieces. One piece of tissue was immediately frozen in liquid nitrogen and subsequently stored in -80°C to be used for metabolomic analysis, gene expression analysis and enzymatic kinetic assays. Another piece of tissue was fixed in 4°C Karnofsky's fixative then processed to Epon 812 embedding for electron microscopy.
A3. Metabolomic Analysis
Tissue extraction for Gas Chromatography (GC) Ten micro liters of N-methyl-N-trimethylsilyltrifluoracetamide (MSTFA) was added automatically via the autosampler and incubated for 60 minutes at 37°C with shaking. After incubation 3 uL of a fatty acid methyl ester standard solution was added via the autosampler then 1 uL of the prepared sample was injected to the gas chromatograph inlet in the split mode with the inlet temperature held at 250°C. A 10:1 split ratio was used for analysis. The gas chromatograph had an initial temperature of 95°C for one minute followed by a 40°C/min ramp to 110°C and a hold time of 2 minutes. This was followed by a second 5°C/min ramp to 250°C, a third ramp to 350°C, then a final hold time of 3 minutes. A 30 m Phenomex ZB5-5 MSi column with a 5 m long guard column was employed for chromatographic separation. Helium was used as the carrier gas at 1 mL/min. Data was extracted from each chromatogram as area under the curve for individual metabolites. Each sample was first normalized to the added standard d4-succinate to account for extraction efficiency followed by normalization to tissue weight. Due to this being a broad scope metabolomics analysis, no normalization for ionization efficiency or concentration standards was performed.
A4. Relative mitochondrial DNA levels (mtDNA):
The cardiac tissue samples were homogenized in lysis buffer [10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.4 mg/ml proteinase K, and 0.1% SDS] and their DNA were subsequently extracted and purified with phenol/chloroform (1). The mitochondrial DNA content was quantified with real-time PCR using SYBR Green PCR master mix and the primers that targeted a stable site in mitochondrial DNA minimal arc and single-copy nuclear DNA within the 2M gene (2). The following primers were used for mitochondria DNA (mtDNAf: CTAAATAGCCCACACGTTCCC, mtDNAr: AGAGCTCCCGTGAGTGGTTA) and nuclear DNA (nuDNAf: GCTGGGTAGCTCTAAACAATGTATTCA, nuDNAr: CCATGTACTAACAAATGTCTAAAATGGT) for qPCR assay on the 7900HT Real-Time PCR System (Applied Biosystem, Foster City, CA) using previously described thermal profile (Phillips NR). The relative mitochondrial DNA content was calculated from the ratio of mitochondrial DNA copy number to nuclear DNA copy number, and the relative fold change was normalized to normal donors (non-failing heart) using the C T method.
A5. Mitochondrial respiratory Flux (JO2):
Immediately after cardiac tissue collection, fat and connective tissue were removed and the remaining cardiac muscle was permeabilized in order to 
